A few observations on our industry's appetite for data from a recent conversation between colleagues in Europe.

The drug pricing debate in DC has intensified, and the pharmaceutical industry has become the prime target of bipartisan outrage.

The drug-price watchdog ICER just issued a "Report on Unsupported Price Increases". The 'study' made the headlines, but it is problematic.

This analysis outlines recent developments in the use of real-world evidence (RWE) and the sizeable impact it stands to make the industry.

Thanks to the team at PharmaVoice for the interview for the "Year in Preview" issue. My two cents on multi-stakeholder commercial models.

Neumann, U. (2018). The Shifting Landscape for Outcomes-Based Contracting – A US Market Assessment (Whitepaper). Analytica Laser.

5 observations as to where we are today, and what might lie ahead for Blockchain in Pharmaceutical Market Access.

Value in Health, Vol. 21, Suppl. 3 S. 165, October, 2018 · Jan 1, 2018

Like anyone who knew him in our field, I am tragically saddened by the passing of Jack Whelan last Thursday. The fact that this day would ev

Neumann, U. (2017). Payer-Pharma Perspectives on Outcomes-based Contracting. Stakeholder Insights. (Whitepaper). Analytica Laser.